NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
19.2%, respectively, on Monday after pharma bigwig Pfizer PFE announced that it is discontinuing the development of its GLP-1R weight loss pill, danuglipron. Pfizer has decided to discontinue the development of its oral obesity drug danuglipron, despite promising results from dose-optimization studies that met key pharmacokinetic goals and showed potential for competitive efficacy and tolerability. Although liver enzyme elevations in the enrolled patients were generally consistent with other approved drugs in the same class, one patient experienced a potential case of drug-induced liver injury, which resolved after stopping treatment with danuglipron. After reviewing all clinical data and considering regulatory feedback, Pfizer concluded that halting the program was the best course of action. This decision reverted Pfizer's developmental program for an obesity candidate back to the early clinical stages and has significantly delayed its hopes for marketing an obesity drug that wou
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss [Yahoo! Finance]Yahoo! Finance
- SA analyst upgrades/downgrades: NVO, INTC, ADBE, WDAY [Seeking Alpha]Seeking Alpha
- EU committee backs extending use of Lilly's diabetes drug for children aged 10 and above [Yahoo! Finance Canada]Yahoo! Finance Canada
- High-end Swiss chocolatier Läderach rules out U.S. production despite tariff shock [CNBC]CNBC
- Weight-loss drug developers line up to tap lucrative market as competition heats up [BNN Bloomberg (Canada)]BNN Bloomberg
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/17/25 - Form 6-K
- NVO's page on the SEC website